

**Date:** 20 July 2019. 98/4/29

**Patient's Name:** S.N.

**Responsible Physician:** Dr. Aghili

**Patient Presentation:**


-A 65 year old female with past history of right breast cancer who underwent MRM(T=2.5cm, LVI+, 16 involved LNs, ER+, PR+, HER2-) and received adjuvant chemoRT, presented with bone pain.

-Bone scan and MRI were suspicious for metastases, but in MRI review metastases was ruled out and bone pain was attributed to Letrozole side effects; so Letrozole was changed to Tamoxifen.

-In her recent PET-CT a suspicious lesion in right liver lobe was reported which biopsy confirmed metastases(ER+, PR+, HER2-, Ki67 30-40%).

**Question:** Which one is more justified now, metastasectomy or systemic therapy?

**Recommended Plan:** Regarding PET-CT review which shows growing liver lesion and one suspicious retroperitoneal LN, systemic therapy is recommended now.



PET-CT of the patient which shows right liver lobe metastatic lesion and suspicious retroperitoneal LN.